|
Total number of patients (N = 44)
|
28
|
16
|
|
Age, y
|
58.8 ± 10.1 (range 33–80)
|
63.2 ± 10.1 (range 47–80)
|
|
Body mass index, kg/m2
|
25.3 ± 5.7
|
27.7 ± 2.8
|
|
Smoking (yes / no)
|
9 / 18 [1]
|
5 / 9 [2]
|
|
Allergies (yes / no)
|
9 / 19
|
5 / 11
|
|
Concomitant diseases
|
2 (0.25–4), range 0–6
|
2 (1–4), range 0–5
|
|
Prior major surgeries
|
3 (2–4), range 1–9
|
1.5 (1–2), range 1–3
|
|
ECOG performance score
|
|
ECOG 0
|
9 (32.1%)
|
7 (43.8%)
|
|
ECOG 1
|
18 (64.3%)
|
9 (56.8%)
|
|
ECOG 2
|
1 (3.6%)
|
–
|
|
Karnofsky index
|
|
100%
|
1 (3.6%)
|
3 (18.8%)
|
|
90%
|
8 (28.6%)
|
4 (25.0%)
|
|
80%
|
14 (50.0%)
|
6 (37.5%)
|
|
≤ 70%
|
5 (17.8%)
|
3 (18.8%)
|
|
Histological type
| |
[1]
|
|
Lobular invasive
|
7 (25.0%)
|
–
|
|
Ductal invasive
|
18 (64.3%)
|
–
|
|
Inflammatory
|
1 (3.6%)
|
–
|
|
Other
|
2 (7.1%)
|
–
|
|
Endometrioid adenocarcinoma
|
–
|
5 (33.3%)
|
|
High-grade adenocarcinoma
|
–
|
8 (53.3%)
|
|
Serous
|
–
|
1 (6.7%)
|
|
Clear cell
|
–
|
1 (6.7%)
|
|
Tumor stage
|
|
T1
|
12 (42.9%)
|
11 (68.8%)
|
|
T2
|
9 (32.1%)
|
1 (6.3%)
|
|
T3 / T4
|
7 (25.0%)
|
4 (25.0%)
|
|
N0
|
9 (32.1%)
|
4 (25.0%)
|
|
N1 / N2
|
18 (64.3%)
|
2 (12.5%)
|
|
NX
|
1 (3.6%)
|
10 (62.5%)
|
|
Metastases outside the peritoneum at the time of first PIPAC (yes / no)
|
21 / 7
|
3 / 13
|
|
Bone
|
14 (50.0%)
|
–
|
|
Liver
|
3 (10.7%)
|
2 (12.5%)
|
|
Pleura
|
5 (17.9%)
|
–
|
|
Other
|
7 (25.0%)
|
1 (6.3%)
|
|
Systemic oncological therapy concurrent with PIPAC (yes / no)
|
23 / 5
|
7 / 9
|
|
Chemotherapy
|
4 (14.3%)
|
–
|
|
Endocrine therapy
|
12 (42.9%)
|
7 (43.8%)
|
|
Bisphosphonates/denosumab
|
11 (39.3%)
|
–
|
|
Other
|
2 (7.1%)
|
–
|
|
Prior chemotherapy lines
|
2, range 0–8
|
1, range 0–2
|
|
Type of chemotherapy
|
|
Anthracycline
|
11 (39.3%)
|
–
|
|
Platinum
|
2 (7.1%)
|
–
|
|
Taxane
|
8 (28.6%)
|
1 (6.3%)
|
|
Anthracycline + platinum
|
–
|
3 (18.8%)
|
|
Anthracycline + taxane
|
9 (32.1%)
|
2 (12.5%)
|
|
Platinum + taxane
|
3 (10.7%)
|
8 (50.0%)
|
|
Other
|
10 (35.7%)
|
1 (6.3%)
|
|
Targeted therapy (yes / no)
|
8 / 20
|
2 / 14
|
|
Bevacizumab
|
3 (10.7%)
|
2 (12.5%)
|
|
Trastuzumab
|
4 (14.3%)
|
–
|
|
Pertuzumab
|
1 (3.6%)
|
–
|
|
Trastuzumab + pertuzumab
|
1 (3.6%)
|
–
|
|
Lapatinib
|
1 (3.6%)
|
–
|
|
Immune checkpoint inhibitor (yes / no)
|
1 / 28
|
0 / 16
|
|
Palbociclib
|
1 (3.6%)
|
–
|
